Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).
暂无分享,去创建一个
A. Yang | H. Kantarjian | G. Garcia-Manero | J. Cortes | F. Ravandi | C. Maroun | R. Martell | S. Luger | V. Klimek | M. Dubay | E. Laille | W. Newsome | J. Dumouchel | Zoumei Li